Leverage patient-reported data and PROMs to improve outcomes in oncology
Bridge the gap between traditional and holistic care
For pharmaceutical companies, the integration and utilisation of Patient Reported Outcomes (PROs) data in oncology care presents unique opportunities. This data can demonstrate patient-centred care, enhance brand value, differentiate in a competitive market, and foster patient trust. PROs are bridging the gap between traditional clinical endpoints and providing a more holistic approach to care. This leads to improved overall patient outcomes.
This paper explores:
- The role of PROs in oncology care
- Impact on patient outcomes and brand perception
- Challenges in integrating and utilising patient-reported data
- Strategies for effective integration of PROs and Patient Reported Outcome Measures (PROMs)
- Pharma’s role in optimising patient-reported data
Download this free paper to understand the essential role of PROs and PROMs in cancer care and subsequent benefits to Pharma.
About Sciensus
Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.
Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.